stonks4u
Sign up free
CSCI logo

CSCI COSCIENS Biopharma Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.72
+0.00 (+0.00%)

COSCIENS Biopharma Inc. is a specialized biopharmaceutical company dedicated to the global development and commercialization of innovative therapeutic and diagnostic products. Its operations extend across Canada, Switzerland, Ireland, Denmark, Germany, the United States, and other international territories. The company's flagship product is Macrilen (macimorelin), an orally administered peptidomim…

Market Cap: $8.57Mwww.cosciensbio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 11Aug 11

Quote

Day Range
$2.72 – $2.72
52-Week Range
$1.75 – $4.61
Volume
$0.00
Market Cap
$8.57M
50-Day Avg
$3.46
200-Day Avg
$3.18
Prev Close
$2.72
Open
$2.72

Valuation & Ratios

P/E Ratio
-0.47
EPS
$-5.93
P/B Ratio
0.54
P/S Ratio
0.52
Debt/Equity
0.18
Current Ratio
3.32
Dividend Yield
+0.0%
Gross Margin
+49.3%

Returns & Efficiency

Return on Equity
-116.3%
Return on Assets
-43.7%
FCF Yield
-220.0%
EV/EBITDA
0.51

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2024$13.78M$-15.31M$-5.93
2023$7.14M$-3.48M$-1.89
2022$14.57M$3.45M$2.54
2021$13.49M$2.64M$1.33
2020$11.86M$1.46M$0.85

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

3of 3 quarters beat consensus

Typical surprise +46.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Apr 9$-2.15 vs $-3.48beat
  • Tue, Nov 12$-1.85 vs $-3.48beat
  • Tue, Aug 13$-0.64 vs $-3.28beat

Estimates and results for CSCI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

CSCIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·3d ago·Neutral

    COSCIENS Biopharma Inc. Reports Q2 2026 Results TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“COSCIENS” or the “Company”) today reported its financial and operating results for the second quarter ended June 30, 2026. All amounts in this press release are in U.S. dollars.

    View source ↗